Cost-effectiveness of cervical cancer prevention

Clinical Obstetrics and Gynecology

Volumn 56, Issue 1, 2013, Pages 55-64

  Esselen, Katharine M ^a   Feldman, Sarah ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cervical cancer prevention; cervical cancer screening; cost effectiveness

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; CLINICAL DECISION MAKING; COLPOSCOPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LOWEST INCOME GROUP; PAPANICOLAOU TEST; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UTERINE CERVIX CANCER; WART VIRUS;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MARKOV CHAINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84873405535     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3182823797     Document Type: Conference Paper

References (23)

1. Fleurence RL, Dixon JM, Milanova TF, et al. Review of the economic and quality-of-life bur-den ofcervical human papillomavirus disease. Am J Obstet Gynecol. 2007;196:206-212.
2. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276:1172-1177.
3. Weinstein MC, Siegel JE, Gold MR, et al. Recom-mendations of the panel on cost-effectiveness in healthandmedicine. JAMA. 1996;276:1253-1258.
4. Dasbach EJ. Mathematical models for predicting the epidemiologic and economic impact of vacci-nation against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88-100.
5. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human papillomavirus and cer-vical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007; 5:11. Available at: http://www.pophealthmetrics.com/content/5/1/11. Accessed January 2, 2013.
6. Tengs TO, Adama ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
7. Saslow D, Solomon D, Lawson HW, et al. Amer-ican cancer society, American society for colpo-scopy and cervical pathology and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
8. Kulasingam S, Havrilesky L, Ghebre R, et al. Screening for Cervical Cancer: A Decision Anal-ysis for the US Preventative Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality.
9. Mandelblatt JS, Fahs MC. The cost-effectiveness of cervical cancer screening for low-income elderlywomen. JAMA. 1988;259:2409-2413.
10. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of papnicolau testing. JAMA. 1999;281:347-353.
11. Myers ER, McCrory DC, Subramanian S, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol. 2000;96:645-652.
12. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372-2381.
13. Kim JJ, Thomas TC, Goldie SJ. Cost-effective-ness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390.
14. Vijayaraghavan A, Efrusy MB, Goodman KA, et al. Cost-effectiveness of using human papillo-mavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol. 2010;119:237-242.
15. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papilloma-virus vaccine to screening programs. JAMA. 2003;290:781-789.
16. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness of cervical cancer screen-ing with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst. 2008;100:308-320.
17. Kim JJ, Ortendahl BS, Goldie SJ. Cost-effective-ness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the united states. Ann Intern Med. 2009;151:538-545.
18. Kim JJ, Goldie SJ. Health and economic implica-tions of HPV vaccination in the United States. N Engl J Med. 2008;359:821-832.
19. Armstrong EP. Prophylaxisofcervicalcancerand related cervical disease: a review of the cost-effec-tiveness of vaccination against oncogenic HPV types. JManag Care Pharm. 2010;16:217-230.
20. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings clinical benefits and cost-effec-tiveness. JAMA. 2001;285:3107-3115.
21. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. For the alliance for cervical cancer preven-tion cost working group cost effectiveness of cervical cancer screening in five developing coun-tries. NEngl JMed. 2005;353:2158-2168.
22. Vijayaraghavan A, Efrusy M, Lindeque G, et al. Cost-effectiveness ofhigh-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol. 2009;112:377-383.
23. Ginsberg GM, Lauer JA, Zelle S, et al. Cost effectiveness of strategies to combat breast, cer-vical and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modeling study. BMJ. 2012;344:e614.